Berenberg Bank Issues Positive Forecast for Hikma Pharmaceuticals (LON:HIK) Stock Price

Hikma Pharmaceuticals (LON:HIK) had its target price upped by equities research analysts at Berenberg Bank from GBX 1,800 to GBX 2,100 in a research note issued to investors on Tuesday,Digital Look reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price target suggests a potential upside of 29.41% from the stock’s previous close.

A number of other brokerages have also commented on HIK. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a research report on Friday. Jefferies Financial Group upped their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hikma Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of GBX 2,098.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 1,622.71 on Tuesday. Hikma Pharmaceuticals has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,865. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The company has a market capitalization of £3.39 billion, a price-to-earnings ratio of 8.97, a P/E/G ratio of 2.38 and a beta of 0.66. The stock’s fifty day simple moving average is GBX 1,538.45 and its 200-day simple moving average is GBX 1,453.55.

Insider Activity at Hikma Pharmaceuticals

In other news, insider Tobias Hestler acquired 7,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of GBX 1,648 per share, for a total transaction of £123,600. Insiders own 22.04% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.